Exelixis | EXEL - Equity Capital And Reserves


Exelixis reported $2.16B in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 917.27M 94.89M Sep/2025
Agios Pharmaceuticals USD 1.28B 85.22M Sep/2025
Amgen USD 9.62B 2.19B Sep/2025
AstraZeneca USD 45.89B 1.17B Sep/2025
Bayer EUR 29.7B 799M Sep/2025
BioMarin Pharmaceutical USD 6.06B 29.6M Sep/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Cytokinetics USD -521.12M 216.32M Sep/2025
Eisai JPY 854.43B 25.92B Sep/2025
Eli Lilly USD 23.79B 5.52B Sep/2025
Exelixis USD 2.16B 127.16M Sep/2025
Genmab DKK 5.3B 6M Jun/2025
Glaxosmithkline GBP 21.7B 7.35B Sep/2025
Incyte USD 4.65B 480.29M Sep/2025
Ionis Pharmaceuticals USD 617.97M 13.76M Sep/2025
MacroGenics USD 67M 20.38M Sep/2025
Merck USD 51.85B 2.79B Sep/2025
Moderna USD 9.33B 69M Sep/2025
Neurocrine Biosciences USD 3B 309.3M Sep/2025
Novartis USD 44.75B 2.7B Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Sanofi EUR 71.71B 14.25B Dec/2025
Takeda JPY 7.64T 513.39B Dec/2025
Ultragenyx Pharmaceutical USD 9.16M 142.13M Sep/2025
Xencor USD 625.32M 4.96M Sep/2025